August 20, 2025
The FDA has lifted REMS requirements for all approved CAR-T therapies, a move that could transform access for patients and research sites alike. What does this mean for trial participation, site activation, and the future of cell and gene therapy? Read on to see how this shift reshapes the CAR-T landscape.